MedTrace Logo

Comparative Study Between Oral Liposomal Iron,Iron Supported Lactoferrin and IV Iron Dextran in CKD Children

NCT05714176 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-02-06

No results posted yet for this study

Summary

This is a randomized, parallel study that will be conducted on pediatric patients with CKD.

Conditions

  • CKD - Chronic Kidney Disease

Interventions

DRUG

Ferric Pyrophosphate Liposomal

30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.

DRUG

Lactoferrin

30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.

DRUG

Iron Dextran Injection

30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Menoufia University

    lead OTHER

Principal Investigators

  • Sahar K Hagazy, PhD · Tanta University

  • Mohamed SH Al-Haron · Menoufia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-01-31
Completion
2024-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05714176 on ClinicalTrials.gov